<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04975295</url>
  </required_header>
  <id_info>
    <org_study_id>17291</org_study_id>
    <secondary_id>I9S-MC-BTAC</secondary_id>
    <secondary_id>2019-003187-40</secondary_id>
    <nct_id>NCT04975295</nct_id>
  </id_info>
  <brief_title>A Study of LY3361237 in Participants With Psoriasis</brief_title>
  <official_title>A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Participants With Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn more about the safety and tolerability of&#xD;
      LY3361237 and any side effects that might be associated with it when given to participants&#xD;
      with psoriasis. LY3361237 will be administered by injections just under the skin. The study&#xD;
      will last up to 41 weeks and may include up to 15 visits to the study center.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2021</start_date>
  <completion_date type="Anticipated">October 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 14, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Day 253</time_frame>
    <description>A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Minimum Serum Concentration (Cmin) of LY3361237 During the Dosing Interval</measure>
    <time_frame>Day 1 predose through Day 253</time_frame>
    <description>PK: Cmin of LY3361237 During the Dosing Interval</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>LY3361237</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3361237 administered subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3361237</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3361237</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have chronic plaque psoriasis for at least 6 months&#xD;
&#xD;
          -  Be willing and able to undergo skin biopsies&#xD;
&#xD;
          -  Body mass index (BMI) within the range of 18 to 40 kilograms per meter squared (kg/mÂ²)&#xD;
&#xD;
          -  Female participants must agree to use birth control during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have had certain types of infection within the last six months&#xD;
&#xD;
          -  Have a clinically significant active infection, or recent acute active infection&#xD;
             within the last 30 days&#xD;
&#xD;
          -  Have other serious or unstable illnesses&#xD;
&#xD;
          -  Have a history of organ or bone marrow transplant&#xD;
&#xD;
          -  Have received any live vaccine within the last 4 weeks prior to screening&#xD;
&#xD;
          -  Have received systemic nonbiologic psoriasis therapy within 4 weeks prior to study day&#xD;
             1&#xD;
&#xD;
          -  Have received topical psoriasis treatment within 14 days prior to study day 1&#xD;
&#xD;
          -  Have excessive skin exposure or use tanning booths for at least 4 weeks prior to study&#xD;
             day 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MC Comac Medical</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>359 2 850 97 04</phone>
    </contact>
    <investigator>
      <last_name>Lyubomir Dourmishev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Budai Irgalmasrendi Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>36302995005</phone>
    </contact>
    <investigator>
      <last_name>Bernadette Rojkovich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Med - Lodz</name>
      <address>
        <city>Lodz</city>
        <zip>94048</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>504273631</phone>
    </contact>
    <investigator>
      <last_name>Agnieszka Zebrowska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ai Centrum Medyczne Sp. Z O.O. Sp.K.</name>
      <address>
        <city>Poznan</city>
        <zip>61-113</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>48 603 309 321</phone>
    </contact>
    <investigator>
      <last_name>Anna Rychlewska-Hanczewska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WIP Warsaw IBD Point Profesor Kierkus</name>
      <address>
        <city>Warszawa</city>
        <zip>00-728</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>605130203</phone>
    </contact>
    <investigator>
      <last_name>Agnieszka Kardynal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pratia - Warsaw</name>
      <address>
        <city>Warszawa</city>
        <zip>01-868</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>48531419850</phone>
    </contact>
    <investigator>
      <last_name>Ewelina Bialo-Wojcicka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summit Clinical Research, s.r.o. - Bratislava</name>
      <address>
        <city>Bratislava</city>
        <zip>831</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>421254131490</phone>
    </contact>
    <investigator>
      <last_name>Danka Svecova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Slovakia</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/5M4E6fdkjelSDEBizWd8Bg</url>
    <description>A Study of LY3361237 in Participants With Psoriasis</description>
  </link>
  <verification_date>September 15, 2021</verification_date>
  <study_first_submitted>July 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

